Amgen Inc.
Vector Securities International analyst Gregory Brown lowered his recommendation on Amgen Inc. to "neutral" from "buy," stating that the Thousand Oaks, Calif., company is within 5 percent of Vector's $57 price target. The downgrade was made in view of AMGN's strong price performance since the firm issued a "buy" earlier this year, and the apparent lack of any potential strong upside surprises in the next few months.